Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
500

Summary

Conditions
  • Hematologic Cancers
  • Metastatic Cancers
  • Solid Tumors
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a biology driven, trans-tumoral, multicentric phase II trial assessing the efficacy and the safety of the targeted agent vemurafenib as a monotherapy in cohorts of patients with identified activating molecular alterations in BRAF gene. A cohort is defined by a pathology and a BRAF- alteratio...

This is a biology driven, trans-tumoral, multicentric phase II trial assessing the efficacy and the safety of the targeted agent vemurafenib as a monotherapy in cohorts of patients with identified activating molecular alterations in BRAF gene. A cohort is defined by a pathology and a BRAF- alteration (eg ovarian cancer with BRAF V600 mutation). To explore the efficacy of vemurafenib per pathology and per target. To assess the safety profile of vemurafenib. To explore whether molecularly driven, high quality multi-tumor screening phase II trials are feasible in the French multiinstitutional, multidisciplinary setting. To investigate the additional molecular mechanisms in patients with tumor response versus patients without tumor response within the same cohort. The study will include 11 cohorts of adult patients with the following cancers and alterations: NSCLC V600 mutated Ovarian cancer V600 mutated Cholangiocarcinoma V600 mutated Thyroid cancer V600 mutated Prostatic cancer V600 mutated Bladder cancer V600 mutated Sarcoma/GIST V600 mutated Multiple myeloma V600 mutated Chronic Lymphocytic Leukemia (CLL) V600 mutated Hairy cell leukaemia (HCL) V600 mutated (this excludes Hairy Cell Leukemia variant types, marginal zone splenic lymphoma (MZL), splenic red pulp lymphoma (SRPL) patients) Other pathology / other alteration than those pre-defined above. The cohort named "Other" will include adult patients with tumor harboring BRAF genomic alterations only tested via emerging biomarkers programs or molecular pangenomic programs: with any other non-predefined pathology harboring a V600 mutation Same or other non-predefined pathology harboring non V600 activating mutations Same or other non-predefined pathology harboring BRAF amplifications.

Tracking Information

NCT #
NCT02304809
Collaborators
  • National Cancer Institute, France
  • Fondation ARC
  • Hoffmann-La Roche
Investigators
Principal Investigator: Jean-Yves PI Blay, MD CCLC LEON BERARD LYON